[{"orgOrder":0,"company":"4SC AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Domatinostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"4SC AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"4SC AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4SC AG \/ Inapplicable"},{"orgOrder":0,"company":"4SC AG","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Domatinostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"4SC AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"4SC AG \/ Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"4SC AG \/ Merck Group"},{"orgOrder":0,"company":"4SC AG","sponsor":"4SC AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Nivolumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I","graph3":"4SC AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"4SC AG \/ 4SC AG","highestDevelopmentStatusID":"6","companyTruncated":"4SC AG \/ 4SC AG"},{"orgOrder":0,"company":"4SC AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compounds","year":"2021","type":"Inapplicable","leadProduct":"14-C Resminostat","moa":"HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"4SC AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"4SC AG \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"4SC AG \/ Inapplicable"}]